Meadow Creek Investment Management LLC Reduces Stock Holdings in Kura Oncology Inc (NASDAQ:KURA)

Share on StockTwits

Meadow Creek Investment Management LLC lowered its position in Kura Oncology Inc (NASDAQ:KURA) by 47.8% in the second quarter, HoldingsChannel reports. The institutional investor owned 1,652 shares of the company’s stock after selling 1,512 shares during the period. Meadow Creek Investment Management LLC’s holdings in Kura Oncology were worth $33,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Meeder Asset Management Inc. increased its position in shares of Kura Oncology by 164.9% in the second quarter. Meeder Asset Management Inc. now owns 1,934 shares of the company’s stock valued at $38,000 after buying an additional 1,204 shares in the last quarter. Bank of Montreal Can increased its position in Kura Oncology by 82,066.7% during the 2nd quarter. Bank of Montreal Can now owns 2,465 shares of the company’s stock worth $49,000 after purchasing an additional 2,462 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Kura Oncology by 599.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock worth $56,000 after purchasing an additional 2,420 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Kura Oncology during the 2nd quarter worth about $59,000. Finally, BNP Paribas Arbitrage SA increased its position in Kura Oncology by 293,950.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 5,881 shares of the company’s stock worth $98,000 after purchasing an additional 5,879 shares in the last quarter. Institutional investors and hedge funds own 85.47% of the company’s stock.

A number of analysts recently commented on the company. Deutsche Bank assumed coverage on Kura Oncology in a research report on Thursday, July 18th. They set a “buy” rating and a $28.00 price objective for the company. Citigroup lifted their price objective on Kura Oncology from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, May 24th. BidaskClub cut Kura Oncology from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 4th. HC Wainwright reiterated a “buy” rating and set a $29.00 price objective on shares of Kura Oncology in a research report on Friday, August 2nd. Finally, Cowen restated a “buy” rating on shares of Kura Oncology in a report on Monday, June 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $27.10.

Kura Oncology stock traded up $0.25 during midday trading on Thursday, hitting $16.86. 2,921 shares of the company were exchanged, compared to its average volume of 200,787. The company’s fifty day moving average price is $17.09 and its 200-day moving average price is $17.04. The company has a market cap of $739.26 million, a PE ratio of -9.59 and a beta of 2.59. The company has a debt-to-equity ratio of 0.03, a current ratio of 23.50 and a quick ratio of 23.50. Kura Oncology Inc has a fifty-two week low of $10.20 and a fifty-two week high of $21.42.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.03. On average, analysts expect that Kura Oncology Inc will post -1.61 EPS for the current fiscal year.

In related news, insider Antonio Gualberto sold 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $21.11, for a total transaction of $379,980.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 11.00% of the company’s stock.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

See Also: Are FAANG stocks a good investment?

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology Inc (NASDAQ:KURA).

Institutional Ownership by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.